Cytology Reflex to cell block and relevant IHC Body fluid

Cancer

Report in 168Hrs

At Home

No Fasting Required

Details

Cytology + immunohistochemistry of fluids.

₹518₹740

30% OFF

Cytology Reflex to Cell Block and Relevant IHC Body Fluid - Complete Medical Guide

Section 1: Why is it done?
- Test Purpose: This test examines cells from body fluids (pleural, peritoneal, pericardial, cerebrospinal) using cytology with automatic reflex to cell block preparation and immunohistochemistry (IHC) staining when abnormal cells are detected. It identifies malignant cells, infectious organisms, and inflammatory conditions.
- Primary Indications: Suspected malignancy in body fluids; diagnosis of metastatic disease; evaluation of pleural effusions, ascites, pericardial effusions, or cerebrospinal fluid abnormalities; characterization of neoplastic cells; determination of cancer type and origin
- Clinical Circumstances: Performed when initial cytology screening reveals atypical or suspicious cells; when morphology alone is insufficient for diagnosis; during cancer staging and surveillance; when specific tumor markers or cell phenotyping is needed for treatment planning
- Reflex Mechanism: Automatic progression from routine cytology to cell block preparation occurs when abnormal findings are identified, followed by targeted IHC panels to improve diagnostic accuracy and classify malignant processes
Section 2: Normal Range
- Normal Findings (Negative Results): No malignant cells present; cellular composition appropriate for fluid type (mesothelial cells, lymphocytes, macrophages); absence of atypical cells; normal inflammatory pattern if any; negative for suspicious morphology
- Benign Results: Category I - Negative for malignancy (no reflex testing needed); reactive mesothelial cells; benign lymphoid aggregates; infectious organisms with benign inflammatory response
- Borderline/Atypical Results: Category II - Atypia of undetermined significance (AUS); reactive changes suspicious for malignancy; reflex to cell block and IHC recommended for further classification
- IHC Panel Reference Range: Results reported as positive, negative, or equivocal for specific markers; intensity graded as negative (-), weak (+), moderate (++), or strong (+++); percentage of positive cells documented; interpretation based on established immunophenotypic profiles for specific malignancies
- Units of Measurement: Qualitative assessment (positive/negative); semi-quantitative intensity scoring; percentage of staining positive cells; categorical classification per established cytopathology reporting systems
Section 3: Interpretation
- Category I - Negative for Malignancy: No malignant cells identified; effusion likely due to benign cause (infection, inflammation, congestive heart failure); no reflex testing performed; low risk for malignant disease; clinical correlation recommended
- Category II - Atypia of Undetermined Significance: Automatic reflex triggered; cell block preparation performed; targeted IHC panel applied; helps differentiate reactive changes from malignancy; intermediate risk category; often requires clinical follow-up
- Category III - Suspicious for Malignancy: Reflex to cell block and IHC mandatory; morphologic features highly concerning but not diagnostic; IHC may confirm malignancy and provide cell type; higher risk; often warrants clinical investigation and possible tissue biopsy
- Category IV - Positive for Malignancy: Malignant cells definitively identified; cell block and IHC confirm diagnosis; specific tumor type and origin may be determined; high specificity; IHC panel characterizes phenotype (adenocarcinoma, squamous cell, mesothelioma, lymphoma, etc.); facilitates treatment planning
- IHC Marker Interpretation: Positive markers support specific diagnoses (CK7+/CK20+ suggests colorectal origin; TTF-1+ suggests lung/thyroid; mesothelin+ suggests mesothelioma); negative markers exclude certain diagnoses; combination patterns establish immunophenotypic profile; abnormal expression may indicate malignancy or specific tumor subtype
- Factors Affecting Results: Sample quality and cellularity; fixation method; timing of specimen processing; previous chemotherapy or radiation affecting marker expression; specimen contamination; prior malignancy history; inflammatory conditions mimicking malignancy; technical issues with antibody staining
- Clinical Significance of Patterns: Adenocarcinoma pattern (CK7+, CK20+/-, CEA+); squamous cell pattern (p63+, CK5+); mesothelial pattern (calretinin+, WT1+, D2-40+); lymphoma pattern (CD45+, specific B or T cell markers); adenocarcinoma vs mesothelioma discrimination critical for prognosis; organ-specific patterns guide primary site identification
Section 4: Associated Organs
- Primary Organ Systems: Respiratory system (pleural fluid - lung, pleura, mediastinum involvement); gastrointestinal system (peritoneal fluid - liver, pancreas, colon, gastric involvement); cardiovascular system (pericardial fluid - heart, pericardium, mediastinum); central nervous system (cerebrospinal fluid - brain, spinal cord, meninges)
- Common Malignancies Detected: Adenocarcinoma (lung, gastric, ovarian, pancreatic primary); squamous cell carcinoma; small cell carcinoma; mesothelioma (pleural/peritoneal); lymphoma (including leptomeningeal involvement); metastatic melanoma; metastatic breast carcinoma; renal cell carcinoma; hepatocellular carcinoma
- Benign Associated Conditions: Congestive heart failure (pleural effusion); cirrhosis with ascites (peritoneal); pneumonia (pleural); tuberculosis (pleural, peritoneal, CSF); pericarditis (pericardial); meningitis (CSF); pulmonary embolism; nephrotic syndrome; systemic lupus erythematosus
- Infectious Agents Identified: Bacterial (Mycobacterium tuberculosis); fungal (Cryptococcus, Histoplasma, Coccidioides); viral (CMV in CSF); parasitic organisms; opportunistic infections in immunocompromised patients; special stains and cultures may accompany cytology
- Potential Complications/Associated Risks: Delayed diagnosis of metastatic disease; pneumothorax (thoracentesis); infection (peritoneal tap); cardiac tamponade (pericardiocentesis); incorrect primary site identification affecting treatment; false negative results in early malignancy; sampling error if insufficient malignant cells present
- Prognosis Implications: Malignancy in body fluids generally indicates advanced disease (Stage IV); presence of specific markers may indicate tumor behavior and treatment resistance; cell type identification allows targeted therapy selection; mesothelioma diagnosis significantly impacts prognosis and treatment options
Section 5: Follow-up Tests
- Additional Testing for Positive Malignancy Results: Tissue biopsy (primary lesion if not identified); imaging studies (CT, MRI, PET) to stage disease and identify primary; molecular testing (EGFR, KRAS, ALK, PD-L1) if adenocarcinoma suspected; flow cytometry if lymphoma likely; tumor markers (CEA, CA 19-9, CA-125) based on cell type
- Extended IHC Panels: Adenocarcinoma origin panel (CK7, CK20, TTF-1, p63, CDX2); mesothelioma vs adenocarcinoma panel (calretinin, WT1, D2-40, CK5/6, EpCAM); lymphoma phenotyping (CD45, CD20, CD3, CD5, CD10, CD23); Her2/neu, estrogen receptor, progesterone receptor if breast cancer suspected
- Molecular and Genetic Testing: FISH (fluorescence in situ hybridization) for specific translocations; gene mutations (EGFR, ALK, ROS1); microsatellite instability; mismatch repair proteins; PD-L1 expression for immunotherapy eligibility; chromosomal abnormalities in lymphoma
- Complementary Tests: Flow cytometry (for lymphoproliferative disorders); special stains (Gram, AFB, fungal stains) if infection suspected; bacterial/fungal/mycobacterial cultures; electron microscopy if mesothelioma considered; cell ploidy analysis
- Repeat Cytology Recommendations: For Category II (AUS) results: consider repeat effusion sampling in 4-8 weeks if initial sample hypocellular or indeterminate; helps establish trend and confirm diagnosis; low cellular yield may warrant recollection; persistent findings favor malignancy
- Monitoring for Suspected Cases: Category III (suspicious) patients: clinical follow-up at 1-3 months; consider tissue biopsy if feasible; imaging follow-up to assess for progression; repeat effusion analysis if effusion recurs; correlation with clinical presentation essential
- Treatment Monitoring: Repeat body fluid cytology during cancer therapy to assess treatment response; evaluation of effusion resolution or persistence; detection of therapy-resistant disease; serial CEA or tumor markers if initially elevated
Section 6: Fasting Required?
- Fasting Requirement: NO - Fasting is NOT required for this test
- Specimen Collection Timing: Body fluid collection procedure (thoracentesis, paracentesis, pericardiocentesis, lumbar puncture) can be performed at any time of day; no food or fluid restrictions necessary unless procedure itself requires anesthesia (then standard pre-procedure fasting may apply)
- Pre-Procedure Preparation: Informed consent required; explanation of procedure and risks; patient positioning as needed for specific procedure; baseline vital signs; coagulation studies may be checked (PT/INR, platelet count); discontinue anticoagulants as directed by physician; local anesthesia typically used (minimal systemic absorption)
- Medications - No Specific Restrictions: Routine medications may be continued unless otherwise directed; anticoagulants (warfarin, DOACs) should be reviewed with physician - may need temporary discontinuation before procedure; antiplatelet agents (aspirin, clopidogrel) - physician assessment required; maintain regular medication schedule except as instructed
- Special Preparation Instructions: Empty bladder before abdominal procedures; wear comfortable, easily removable clothing; arrange transportation if sedation used; have responsible adult accompany if conscious sedation administered; report any bleeding disorders or medications to provider
- Specimen Handling Requirements: Fluid collected in sterile container without fixative; immediate transport to laboratory critical; room temperature preferred (avoid refrigeration as it may compromise cell preservation); multiple aliquots may be prepared for reflex testing; priority processing for suspicious samples; proper labeling with patient identification, specimen type, and collection time
- Post-Procedure Care: Observe for 30 minutes post-procedure; monitor for complications (pain, bleeding, infection); patients may resume normal diet and activity; slight discomfort common; report shortness of breath, chest pain, fever, or significant bleeding to healthcare provider; activity restrictions per physician directive based on procedure type

How our test process works!